HuidaGene releases update on CRISPR Duchenne trial after months of silence
HuidaGene announced that its CRISPR study for Duchenne muscular dystrophy has been marked as complete, ending a 15-month period without public statements.
At an American Society for Gene and Cell Therapy meeting in New Orleans, HuidaGene CEO Alvin Luk shared preliminary findings from one of the first CRISPR trials targeting Duchenne muscular dystrophy, a lethal childhood disease. The initial two-patient data showed limited effect, and the company planned a higher dose study. Following the presentation, HuidaGene fell silent for 15 months, during which both Luk and CTO TJ Cradick departed.
In February, the trial’s registry entry was updated to indicate completion, prompting one outlet's investigation. On Wednesday the company finally issued a brief statement confirming the study’s end, but offered no information on outcomes for the other enrolled children.
Why it matters
The update raises concerns about transparency and safety oversight in experimental gene-editing trials.
In this story